银诺医药-B(02591.HK) 公布,公司用于治疗2型糖尿病的核心产品依苏帕格鲁肽α于澳门的首张处方已在澳门华宝医疗中心开出,标志着核心产品在澳门正式进入商业化销售阶段。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link银诺医药-B(02591.HK) 公布,公司用于治疗2型糖尿病的核心产品依苏帕格鲁肽α于澳门的首张处方已在澳门华宝医疗中心开出,标志着核心产品在澳门正式进入商业化销售阶段。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.